(Q28247372)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Fabrice André

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Angelo Delmonte

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Maurizio D'Incalci

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Massimo Zucchetti

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Josep Tabernero Caturla

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

14

R Robert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

J-C Soria

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

R Bahleda

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

B Adamo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

R Dienstmann

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

R Cereda

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

J Isaacson

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

J Litten

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

A Allen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

F Dubois

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

C Saba

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

M G Camboni

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

November 2014

0 references

published in

Annals of Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

2244-2251

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

Fibroblast growth factors and their receptors in cancer

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Targeting angiogenesis: progress with anti-VEGF treatment with large molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Regulation of renal phosphate transport by FGF23 is mediated by FGFR1 and FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

CXCR4 activation defines a new subgroup of Sonic hedgehog-driven medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU390

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU390

2 references

Consolidated OpenCitations Corpus – April 2017

930575

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

930575

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

930575

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25193991%20AND%20SRC:MED&resulttype=core&format=json